Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
Unite for World IBD Day and Crohn's and Colitis Awareness Month
Unite for World IBD Day and Crohn's and Colitis Awareness Month

Brisbane, May 14, 2019 AEST (ABN Newswire) - The month of May marks two very important days in the IBD (inflammatory bowel disease) calendar - Crohn's and Colitis Awareness Month, which takes place throughout May and World IBD Day, which is being held this Sunday, 19 May. Both events are designed to raise awareness for Crohn's disease and Ulcerative colitis, and show support to the 10 million people worldwide who live with IBD.

As a company focused on developing products for human gastrointestinal health we are committed to lending our support to both of these initiatives by helping spread the word. If you are interested in learning more or to find out how you can personally get involved, you can visit the following websites:

- Crohn's and Colitis Awareness Month http://www.abnnewswire.net/lnk/8RCBHYN6

- World IBD Day 2019 http://www.abnnewswire.net/lnk/43Y8XT9T

Given the themes for both events are around making IBD more visible and encouraging people to talk more openly about their symptoms and the impact it has on their lives, we will be sharing some personal stories on our social media channels over the coming days. We also invite anyone with first hand experience of living with IBD to email us their stories, either in text format or as a short video piece, which we will then share on the Anatara website or our twitter and Facebook pages. If you would like to do so, please email Hayley van der Meer at hvandermeer@anatara.com.


About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

General inquiries
Steven Lydeamore
CEO
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 25) (Since Published: 5122)